Evaluating the Safety and Contraceptive Efficacy of Relugolix

Recruiting

18 years - 50 years

Female

Phase 3

1020 participants needed

1 Location

Brief description of study

This study is intended to demonstrate the contraceptive efficacy of relugolix combination therapy. Myovant is developing relugolix combination therapy for the indications of the management of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Uterine Fibroids, Endometriosis
Age: 18 years - 50 years
Gender: Female

Women, Ages 18 to 50

Updated on 04 Aug 2024. Study ID: 850525

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Evaluating the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women with Uterine Fibroids or Endometriosis.

Brief description of study

Eligibility of study

Find a site

Interested in the study